Zootechnical feed additives regulation

Summary#

This bill creates a new category called “zootechnical animal food substance” and sets rules for how those products are reviewed, labeled, and sold. It says these products are treated as food additives and must go through the FDA food-additive petition process with extra data about the product’s intended effect and dose. The bill also requires a specific label statement saying the product is not for diagnosing or treating disease in animals.

• Main change: Defines zootechnical animal food substances (products added to animal feed or water to change gut microbiome, reduce foodborne pathogens, or otherwise affect animal structure/function by acting only in the gut) and makes them food additives subject to the food-additive approval process.
• Data required: Petitions for these substances must include all relevant data on the intended effect, the quantity needed, and full reports of investigations and methods.
• Approval standards: FDA may deny approval if a petition fails to show the proposed use will achieve the intended effect under the specified conditions.
• Labeling: Labels must state the product is “Not for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals.” Labels may describe the intended gut- or microbiome-related effects.
• Exclusions: The definition excludes substances intended to treat disease, hormones, certain previously approved drug moieties, ionophores, and any other items excluded by HHS rulemaking.
• Limit on mandates: The bill says the government may not require anyone to use these substances.

What it means for you#

• Animal feed and additive manufacturers

  • Must treat these products as food additives and prepare a food-additive petition with detailed data on effects and dose.
  • Must include the required non-treatment label statement on product labeling.
  • May face extra testing and documentation before bringing new products to market.

• Farmers, livestock producers, and animal owners

  • If you buy or use products that change the animal gut or lower pathogens, those products will be regulated under this new path.
  • Labels will clearly say such products are not intended to diagnose or treat disease.

• Veterinarians

  • Products covered by this law cannot be labeled or claimed as treatments for disease; therapeutic claims would remain under drug rules.
  • May see clearer distinctions between feed additives and drugs.

• Federal regulators (FDA / HHS)

  • Must apply the food-additive review process to these substances and may write rules to exclude other items from the definition.
  • Will have a new set of petition review tasks specific to these products.

• Consumers and food safety

  • The bill focuses on safety and evidence for products that affect food-producing animals’ gut microbiomes or pathogen loads. Any likely effects on food safety depend on what products are approved.

Expenses#

No publicly available information.

• The bill itself does not include a fiscal estimate in the supplied material.
• This could mean additional costs for companies to run studies and prepare petitions.
• It would likely increase FDA review work and could require agency resources to write and implement new rules and to review petitions.
• Label changes and compliance could create costs for manufacturers and distributors.

Proponents' View#

• The bill appears intended to create a clear regulatory path for products that alter animal gut microbiomes or reduce foodborne pathogens in food animals.
• Supporters may argue that requiring data on intended effect and dose improves safety and ensures products actually work as claimed.
• The required label statement aims to prevent misleading therapeutic claims and protect animal and public health.
• The definition and rulemaking authority set boundaries so similar products are treated consistently under the law.
• The explicit statement that the government cannot force use of these products protects producer choice.

Opponents' View#

• One concern is that the requirement for full investigation reports and proof of intended effect could slow market access for new products and increase development costs.
• The bill does not include a public cost estimate, so it is unclear how much extra burden it would place on FDA staffing or industry testing budgets.
• It is unclear how HHS will use its rulemaking power to exclude items from the definition; that uncertainty could create regulatory confusion.
• The labeling requirement could limit how manufacturers communicate legitimate structure/function benefits, depending on how FDA interprets allowable statements.
• The bill focuses on whether a product achieves its intended effect; it may leave open questions about how long reviews take and what kinds of studies FDA will require.